Sachin Pai, M.D., M.S.C.I.
Medical OncologistProgram Leader of Developmental Therapeutics; Assistant Professor of Interdisciplinary Clinical OncologySpecialty: Cancer CareConditions Treated
- Head and Neck Cancer
- Hypopharyngeal Cancer
- Laryngeal Cancer
- Lip and Oral Cavity Cancer
- Lung Cancer
- Mesothelioma
- Metastatic Squamous Neck Cancer
- Nasopharyngeal Cancer
- Neuroendocrine Tumors
- Oropharyngeal Cancer
- Paranasal Sinus and Nasal Cavity Cancer
- Salivary Gland Cancer
Professional Memberships
- American Association for Cancer Research (AACR)
- American Medical Association
- American Society of Clinical Oncology (ASCO)
Board Certifications
- American Board of Internal Medicine
- Certification in Medical Oncology
Education
- Medical School: Kasturba Medical College | Mangalore, India
- Residency: Louisiana State University Health Science Center | Shreveport, LA
- Fellowship: Ochsner Clinic Foundation | New Orleans, LA
- Fellowship: Northwestern Medicine Developmental Therapeutics Institute, Robert H. Lurie Comprehensive Cancer Center (RHLCCC) of Northwestern University | Chicago, IL
Languages
- English
- Hindi
Clinical Trials
INCB 01158-101 (CX-1158-101) - Safety, Pharmacokinetics, and Pharmacodynamics of Escalating Oral Doses of the Arginase Inhibitor INCB001158 (Formerly Known as CB1158) as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid Tumors
Treatment for Lung Cancer
Preoperative Extended Chemotherapy Vs. Chemotherapy Plus Hypofractionated Radiation Therapy for Borderline Resectable Adenocarcinoma of the Head of the Pancreas
Treatment for Pancreatic Cancer
DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (S1609)
Treatment for Rare Tumors
A Phase 1 Study of MK-5890 as Monotherapy and in Combination with Pembrolizumab in Participants with Advanced Solid Tumors
Treatment for Advanced Solid Tumors
A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors
Treatment for Solid Tumors
A PHASE II RANDOMIZED STUDY OF ADJUVANT VERSUS NEOADJUVANT MK-3475 (PEMBROLIZUMAB) FOR CLINICALLY DETECTABLE STAGE III-IV HIGH RISK MELANOMA
Treatment for Melanoma
A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) and CD30-expressing peripheral T-cell lymphoma (PTCL) in adults age 60 and above
Treatment for Hodgkin Lymphoma
A PHASE III, DOUBLE-BLIND,PLACEBO-CONTROLLED, RANDOMIZED STUDY OF IPATASERTIB IN COMBINATION WITH ATEZOLIZUMAB AND PACLITAXEL AS A TREATMENT FOR PATIENTS WITH LOCALLY ADVANCED UNRESECTABLE OR METASTATIC TRIPLE-NEGATIVE BREAST CANCER
Treatment for Breast Cancer
A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Rovalpituzumab Tesirine as Maintenance Therapy Following First-Line Platinum-Based Chemotherapy in Subjects with Extensive Stage Small Cell Lung Cancer (MERU)
Treatment for Lung Cancer
LUNGMAP A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer (Lung-MAP Screening Study)
Treatment for Lung Cancer
A Phase 3, Randomized, Double-blind Trial of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC) (KEYNOTE-641)
Treatment for Lung Cancer
A Phase 3, Randomized, Double-blind Study of Pembrolizumab (MK-3475) Plus Docetaxel Plus Prednisone versus Placebo Plus Docetaxel Plus Prednisone in Participants with Chemotherapy-naïve Metastatic Castration-Resistant Prostate Cancer (mCRPC) who have Progressed on a Next Generation Hormonal Agent (NHA) (KEYNOTE921)
Treatment for Prostrate Cancer
EA5163/S1709 INSIGNA: A Randomized, Phase III Study of Firstline Immunotherapy alone or in Combination with Chemotherapy in Induction/Maintenance or Postprogression in Advanced Nonsquamous Non‐Small Cell Lung Cancer (NSCLC) with Immunobiomarker SIGNature‐driven Analysis
Treatment for Lung Cancer
S1800A, A PHASE II RANDOMIZED STUDY OF RAMUCIRUMAB PLUS MK3475 (PEMBROLIZUMAB) VERSUS STANDARD OF CARE FOR PATIENTS PREVIOUSLY TREATED WITH IMMUNOTHERAPY FOR STAGE IV OR RECURRENT NON-SMALL CELL LUNG CANCER (LUNG-MAP NON-MATCHED SUB-STUDY)
Treatment for Lung Cancer
Phase 2, Open-Label Safety and Efficacy Study of Telisotuzumab Vedotin (ABBV-399) in Subjects with Previously Treated c-Met+ Non-Small Cell Lung Cancer
Treatment for Lung Cancer
A Phase III Randomized Trial to Evaluate the Influence of BCG Strain Differences and T Cell Priming with Intradermal BCG Before Intravesical Therapy for BCG‐Naïve High‐Grade Non‐Muscle Invasive Bladder Cancer.
Treatment for Bladder Cancer